Evaluation of protein biomarkers of prostate cancer aggressiveness

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Rizzardi, Anthony E ^a,b   Rosener, Nikolaus K ^b   Koopmeiners, Joseph S ^c,d   Isaksson Vogel, Rachel ^c   Metzger, Gregory J ^e   Forster, Colleen L ^e   Marston, Lauren O ^b   Tiffany, Jessica R ^b   McCarthy, James B ^b   Turley, Eva A ^f   Warlick, Christopher A ^e   Henriksen, Jonathan C ^a,b,e   Schmechel, Stephen C ^a,b,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Aggressiveness; Biomarker; Prostate cancer; Signature

Indexed keywords

CCND1 PROTEIN; HMMR PROTEIN; MKI67 PROTEIN; PROTEIN; SIAH2 PROTEIN; SMAD4 PROTEIN; SOMATOMEDIN; UNCLASSIFIED DRUG; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ANALYTIC METHOD; ARTICLE; AUTOMATED DIGITAL PATHOLOGY TECHNIQUE; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY; AGED; BIOSYNTHESIS; BLOOD; CANCER STAGING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

AGED; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897960735     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-244     Document Type: Article

References (62)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007, 177(2):540-545. 10.1016/j.juro.2006.10.097, 17222629.
3. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993, 149(3):516-518.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597. 10.1001/jama.281.17.1591, 10235151.
5. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin 2001, 28(3):555-565.
6. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006, 8(1):59-68. 10.1593/neo.05664, 1584291, 16533427.
7. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470(7333):269-273. 10.1038/nature09677, 3753179, 21289624.
8. Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004, 112(1):121-129. 10.1002/ijc.20368, 15305383.
9. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115(6):1503-1521. 10.1172/JCI23412, 1136989, 15931389.
10. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004, 113(6):913-923. 10.1172/JCI20032, 362118, 15067324.
11. Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res 2010, 3(1):1-7. 2981422, 21139802.
12. Korkes F, Castro MG, Zequi SD, Nardi L, Giglio LA, Peo AC. RHAMM immunohistochemical expression and androgen deprivation in normal peritumoural, hyperplasic and neoplastic prostate tissue. BJU international 2013, doi:10.1111/bju.12339. [Epub ahead of print].
13. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004, 101(3):811-816. 10.1073/pnas.0304146101, 321763, 14711987.
14. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer cell 2010, 18(1):23-38. 10.1016/j.ccr.2010.05.024, 2919332, 20609350.
15. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer cell 2002, 1(2):203-209. 10.1016/S1535-6108(02)00030-2, 12086878.
16. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, Gerald WL. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005, 104(2):290-298. 10.1002/cncr.21157, 1852494, 15948174.
17. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 2009, 69(10):1119-1127. 10.1002/pros.20961, 3425355, 19343730.
18. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004, 22(14):2790-2799. 10.1200/JCO.2004.05.158, 15254046.
19. Swanson GP, Basler JW. Prognostic factors for failure after prostatectomy. J Cancer Educ 2010, 2:1-19.
20. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648. 10.1126/science.1117679, 16254181.
21. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 2012, 18(24):6648-6657. 10.1158/1078-0432.CCR-12-2715, 3525716, 23052253.
22. Metzger GJ, Dankbar SC, Henriksen J, Rizzardi AE, Rosener NK, Schmechel SC. Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides. PloS One 2012, 7(3):e33520. 10.1371/journal.pone.0033520, 3305321, 22438942.
23. Sagnak L, Topaloglu H, Ozok U, Ersoy H. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clin Genitourin Cancer 2011, 9(2):73-80. 10.1016/j.clgc.2011.07.003, 22035833.
24. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002, 5(2):123-127. 10.1038/sj.pcan.4500572, 12497001.
25. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995, 26(1):106-109. 10.1016/0046-8177(95)90122-1, 7821906.
26. Nanda A, Chen MH, Renshaw AA, D'Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009, 74(5):1419-1423. 10.1016/j.ijrobp.2008.10.027, 19131185.
27. Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011, 81(4):e351-e360. 10.1016/j.ijrobp.2011.01.063, 21493015.
28. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012, 7:42. 10.1186/1746-1596-7-42, 3379953, 22515559.
29. Krajewska M, Smith LH, Rong J, Huang X, Hyer ML, Zeps N, Iacopetta B, Linke SP, Olson AH, Reed JC, Krajewski S. Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem 2009, 57(7):649-663. 10.1369/jhc.2009.952812, 2699321, 19289554.
30. Van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, Rubin DB. Fully conditional specification in multivariate imputation. J Stat Comput Sim 2006, 76(12):1049-1064.
31. van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate Imputation by Chained Equations in R. J Stat Softw 2011, 45(3):1-67.
32. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. J Stat Softw 2011, 39(5):1-13. 3093114, 21572908.
33. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56(2):337-344. 10.1111/j.0006-341X.2000.00337.x, 10877287.
34. Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD. Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 2011, 104(4):693-699. 10.1038/sj.bjc.6606078, 3049587, 21266980.
35. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?. J Cell Sci 2008, 121(Pt 7):925-932.
36. Simpson MA, Lokeshwar VB. Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci 2008, 13:5664-5680. 2630716, 18508614.
37. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009, 11(9):956-963. 2735808, 19724689.
38. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC, Kumar S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 2007, 26(1):58-68. 10.1016/j.matbio.2006.08.261, 17055233.
39. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang JF, Neudecker BA, Wang FS, Turley EA, Naor D. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A 2004, 101(52):18081-18086. 10.1073/pnas.0407378102, 539795, 15596723.
40. Tolg C, Hamilton SR, Zalinska E, McCulloch L, Amin R, Akentieva N, Winnik F, Savani R, Bagli DJ, Luyt LG, Cowman MK, McCarthy JB, Turley EA. A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am J Pathol 2012, 181(4):1250-1270. 10.1016/j.ajpath.2012.06.036, 3463631, 22889846.
41. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, Moreno CS. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005, 24(1):188-198. 10.1038/sj.onc.1207906, 15637592.
42. McCabe CD, Spyropoulos DD, Martin D, Moreno CS. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008, 68(6):1988-1996. 10.1158/0008-5472.CAN-07-5843, 2584783, 18339881.
43. Moon SM, Kim SA, Yoon JH, Ahn SG. HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression. J Biol Chem 2012, 287(42):35678-35688. 10.1074/jbc.M112.361675, 3471680, 22896703.
44. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006, 103(10):3775-3780. 10.1073/pnas.0600040103, 1383649, 16537454.
45. Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, Li JL, Ding YQ, Li JM. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol 2010, 220(4):475-489.
46. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011, 17(4):710-720. 10.1158/1078-0432.CCR-10-0331, 21196414.
47. Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012, 208(9):541-548. 10.1016/j.prp.2012.06.001, 22824148.
48. Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstatter A, Summerer M, Reichhart E, Schafer G, Klocker H. Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment. Am J Pathol 2011, 179(6):2905-2919. 10.1016/j.ajpath.2011.08.026, 3260840, 21983635.
49. Montagnani Marelli M, Moretti RM, Procacci P, Motta M, Limonta P. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol 2006, 28(3):723-730.
50. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 2003, 63(18):5850-5858.
51. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 2000, 97(7):3455-3460. 10.1073/pnas.97.7.3455, 16261, 10737798.
52. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008, 149(7):461-471. W483-468, 10.7326/0003-4819-149-7-200810070-00006, 2584869, 18838726.
53. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 2010, 10:599. 2988752, 21044312.
54. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997, 15(9):1111-1114. 10.1038/sj.onc.1201232, 9285566.
55. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005, 23(9):2078-2093. 10.1200/JCO.2005.02.047, 15774796.
56. Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 2004, 59(3):234-242. 10.1002/pros.10361, 15042598.
57. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Ross JS. Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas. Hum Pathol 2005, 36(11):1204-1209. 10.1016/j.humpath.2005.08.015, 16260274.
58. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Rechberger T, Jakowicki JA, Krajewska WM. TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecol Oncol 2004, 95(1):173-180. 10.1016/j.ygyno.2004.06.032, 15385128.
59. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005, 102(39):13909-13914. 10.1073/pnas.0506517102, 1236573, 16172383.
60. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD, Ronai Z. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 2004, 117(7):941-952. 10.1016/j.cell.2004.06.001, 15210114.
61. Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer cell 2013, 23(3):332-346. 10.1016/j.ccr.2013.02.016, 3750989, 23518348.
62. Koopmeiners JS, Vogel RI. Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med 2013, 32(6):1027-1037. 10.1002/sim.5622, 3888241, 23413213.